-
Northeast Pharmaceutical to Acquire Majority Stake in Dingcheng Peptide Source for RMB 186.8 Million
•
China-based Northeast Pharmaceutical Co., Ltd (SHE: 000597) has announced its intention to acquire a 70% stake in Beijing Dingcheng Peptide Source Biotechnology Co., Ltd, a fellow Chinese firm, for a consideration of RMB 186.8 million. This strategic move is aimed at bolstering Northeast Pharmaceutical’s presence in the cell therapy sector.…
-
Northeast Pharmaceutical to Acquire Majority Stake in Cell Therapy Specialist Dingcheng Taiyuan
•
Northeast Pharmaceutical Co., Ltd (SHE: 000597), a Chinese pharmaceutical company, has announced plans to acquire a 70% stake in Beijing Dingcheng Taiyuan Biotechnology Co., Ltd, a biotech firm specializing in cell therapies for solid tumors. Financial details of the transaction have not been disclosed. Established in 2014, Dingcheng Taiyuan has…
-
Northeast Pharmaceutical Partners with Muscat Changming for Middle East Expansion
•
China-based Northeast Pharmaceutical Co., Ltd (SHE: 000597) has entered into an investment framework agreement with Muscat Changming Investments LLC, leveraging business development plans and market demand in Oman and the Middle East. Joint Venture Establishment and ObjectivesThe partnership aims to establish a joint venture (JV) in the Sultanate of Oman,…
